Founded in 1972, Eurofarma is one of the largest pharmaceutical industries in Brazil. With 100% nati...
Founded in 1972, Eurofarma is one of the largest pharmaceutical industries in Brazil. With 100% national capital, it is proud to be the first pharmaceutical multinational in Brazil. It is present in more than 20 countries and covers 87% of the Latin American market. Elected one of the 20 most innovative companies in Brazil, it launched the first biosimilar medicine in Latin America in 2016. The company is the only bi-champion pharmaceutical company by the Exame de Sustentabilidade Guide.
Founded in 1972, Eurofarma is one of the largest pharmaceutical industries in Brazil. With 100% nati...
Founded in 1972, Eurofarma is one of the largest pharmaceutical industries in Brazil. With 100% national capital, it is proud to be the first pharmaceutical multinational in Brazil. It is present in more than 20 countries and covers 87% of the Latin American market. Elected one of the 20 most innovative companies in Brazil, it launched the first biosimilar medicine in Latin America in 2016. The company is the only bi-champion pharmaceutical company by the Exame de Sustentabilidade Guide.
Founded in 1972, Eurofarma is one of the largest pharmaceutical industries in Brazil. With 100% nati...
Founded in 1972, Eurofarma is one of the largest pharmaceutical industries in Brazil. With 100% national capital, it is proud to be the first pharmaceutical multinational in Brazil. It is present in more than 20 countries and covers 87% of the Latin American market. Elected one of the 20 most innovative companies in Brazil, it launched the first biosimilar medicine in Latin America in 2016. The company is the only bi-champion pharmaceutical company by the Exame de Sustentabilidade Guide.
Founded in 1972, Eurofarma is one of the largest pharmaceutical industries in Brazil. With 100% nati...
Founded in 1972, Eurofarma is one of the largest pharmaceutical industries in Brazil. With 100% national capital, it is proud to be the first pharmaceutical multinational in Brazil. It is present in more than 20 countries and covers 87% of the Latin American market. Elected one of the 20 most innovative companies in Brazil, it launched the first biosimilar medicine in Latin America in 2016. The company is the only bi-champion pharmaceutical company by the Exame de Sustentabilidade Guide.